



September 6, 2017

## Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan (learn more at [www.iaslc.org](http://www.iaslc.org)).

**Title:** Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy

**Oral Presentation Session:** MA 02 - Emerging Targets; Mini Oral

**Presentation Topic:** 04. Clinical Design, Statistics and Clinical Trials

**Location:** Room 511 + 512

**Date and Time:** October 16, 11:00 — 12:30 JST

**Abstract ID:** 9720

**Presenter:** Ticiana A. Leal, M.D.

**Title:** CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib

**Poster Session:** P3.01 - Poster Session with Presenters Present

**Poster Topic:** 01. Advanced NSCLC

**Location:** Exhibit Hall, Hall B+C

**Abstract ID:** 9560

**Presentation Date and Time:** October 18, 9:30 — 16:00 JST

**Presenter:** Lyudmila A. Bazhenova, M.D.

### About Mirati Therapeutics

Mirati Therapeutics is a clinical-stage oncology company developing targeted drugs to address the genetic, epigenetic and immunological promoters of cancer. Our precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, we are advancing clinical programs where the ability of our drugs to improve the immune environment of tumor cells may enhance and expand the efficacy of existing immunotherapy medicines when given in combination. Our pre-clinical programs include potentially first-in-class and best-in-class drugs specifically designed to address mutations and tumors where few treatment options exist. We approach each of our discovery and development programs with a singular focus: to translate our deep understanding of the molecular drivers of cancer into better drugs and better outcomes for patients. For more information, visit [www.mirati.com](http://www.mirati.com).



View original content with multimedia: <http://www.prnewswire.com/news-releases/sitravatinib-data-to-be-highlighted-at-the-iaslc-18th-world-conference-on-lung-cancer-300514883.html>

SOURCE Mirati Therapeutics, Inc.

News Provided by Acquire Media